Long-Term Debt: Poseida (PSTX)

Brandmark of Poseida Corp (PSTX)

Poseida Therapeutics (PSTX) is developing innovative cancer treatments using non-viral PiggyBac gene delivery, which enables the company to dictate favorable terms in licensing contracts. This high-tech foundation creates a closed development loop, tying major market players to B2B agreements. This daily price chart reflects that the company's stability is supported by partner advances at the level of 0.08, providing a solid financial foundation even in the absence of mass sales.

PSTX (Poseida) Company Long-Term Debt history from 07/04/2022 to 01/18/2025

Poseida - analytical breakdowns and key metrics (PSTX)

- current quotes and average value forecast:
Stock Quotes poseida.com|PSTX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Poseida Therapeutics|PSTX - Total Company Value
- book capitalization data:
Net Assets per Single Share Poseida Therapeutics|PSTX - Company Book Value|Market-to-Book Ratio poseida.com|PSTX - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Poseida Therapeutics|PSTX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Poseida Corp|PSTX - Company Total Debt|Debt to Net Assets Ratio Poseida Therapeutics|PSTX - Company Long-Term Debts|Company Current Liabilities Poseida Therapeutics
Fundamental company valuation:poseida.com
Core merchandise of Poseida Therapeutics, Inc.

For the biopharmaceutical sector, Poseida Therapeutics (PSTX) finds credit load management critical when financing costly R&D projects. This indicator aggregates all liabilities with a maturity of over one year, reflecting long-term financial stability. By analyzing the company's long-term debt, investors can track debt dynamics without reporting period delays. A decrease in this metric confirms the effectiveness of strategic partnerships with pharma behemoths. A stable level of liabilities guarantees the uninterrupted development of gene therapy.

Who Poseida Therapeutics competes with

LEGN - Company Long-Term Liabilities|SANA - Company Long-Term Debt|Long-Term Debt Autolus Therapeutics PLC|Allogene Therapeutics Inc (ALLO) - Company Long-Term Debt|RNAC (Selecta Biosciences Inc.) - Company Long-Term Debt|Company Long-Term Debt Cellectis SA|Long-Term Debt cariboubio.com CRBU|Company Long-Term Debts TIL|genenta.com (GNTA) - Long-Term Indebtedness|Century Therapeutics, Inc. - Company Long-Term Liabilities|Jasper Therapeutics Inc (JSPR) - Long-Term Debt|SNTI: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings ADAP (Adaptimmune)|CERO: Company Long-Term Debts|Company Long-Term Liabilities Alaunos Therapeutics, Inc.|ACHL (Achilles Therapeutics PLC) - Company Long-Term Debts|Long-Term Debt CARGO Therapeutics, Inc CRGX|Company Long-Term Debt 2seventy bio, Inc. (TSVT)|Company Long-Term Debt GRCL (gracellbio.com)